Figure 1.
One-way analysis of variance box plots illustrating the observed changes in the levels of aspartate, alanine, and N-carbamoyl-L-aspartate when treated with FK866 at 50 and 5 nM concentrations in A2780 (left panels) and HCT-116 (right panels) cells, respectively, with (+NA) and without (−NA) nicotinic acid addition.
Grand mean is shown as a horizontal line located within panel. The y-axis illustrates normalized, log transformed, and scaled peak area. Dots represent samples. Group mean shown as a horizontal line within the box.
Figure 2.
One-way analysis of variance box plots illustrating the observed level changes in the selected purines: inosine monophosphate (IMP), adenosine, and inosine after FK866 treatment at 50 and 5 nM concentrations in A2780 (left panels) and HCT-116 (right panels) cells, respectively, with (+NA) and without (−NA) nicotinic acid addition.
Grand mean is shown as a horizontal line located within panel. The y-axis illustrates normalized, log transformed, and scaled peak area. Dots represent samples. Group mean shown as a horizontal line within the box.
Figure 3.
One-way analysis of variance box plots illustrating the observed level changes in the detected carnitines after FK866 treatment at 50 and 5 nM concentrations in A2780 (left panels) and HCT-116 (right panels) cells, respectively, with (+NA) and without (−NA) nicotinic acid addition.
Grand mean is shown as a horizontal line located within panel. The y-axis illustrates normalized, log transformed, and scaled peak area. Dots represent samples. Group mean shown as a horizontal line within the box.
Figure 4.
Unsupervised hierarchical clustering analysis of the metabolite levels in A2780 (left panels) and HCT-116 (right panels) cells after FK866 treatment at 50 and 5 nM concentrations, respectively, with (+NA) and without (−NA) nicotinic acid addition.
Elevated metabolite levels are red and depressed ones are green. Each square represents the Pearson correlation coefficient between the metabolite in the row with the group in the column.
Figure 5.
Molecule activity prediction for amino acid metabolism, lipid metabolism, and molecular transport networks illustrating the treatment of HCT-116 cells with 50 nM of FK866 without nicotinic acid (left panel) and with addition of nicotinic acid (right panel). Blue nodes color reflects inhibition. Orange nodes explain activation. Color intensity depicts the degree of relative concentration for metabolites or activation for the proteins/complexes. Red metabolite nodes illustrate the elevated levels measured. Green metabolite nodes illustrate the decreased levels measured. Solid lines represent the direct relationships between nodes. Dotted lines represent indirect relationships between nodes. Red colored lines point to activation and blue to inhibition. Yellow lines indicate an inconsistent state of a downstream molecule. Ldh – lactate dehydrogenase, Akt - protein kinase B, FAD - flavin adenine dinucleotide, Nos - nitric oxide synthase, PRKAA - AMP-activated protein kinase, AICAR - 5-Aminoimidazole-4-carboxamide ribonucleotide.
Figure 6.
ADA, adenosine deaminase; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMP, adenosine monophosphate; GMP, guanosine monophosphate; GSK, inosine kinase; IMP, inosine monophosphate; IMPDH, inosine 5′-monophosphate dehydrogenase; PNase, purine 5′-nucleotidase; PNPase, purine-nucleoside phosphorylase; PRPP, 5-phospho-α-ribosyl-1-pyrophosphate; S-AMP, succinyl adenosine monophosphate.